Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-12
2011-07-12
Chu, Yong (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S397000, C548S255000
Reexamination Certificate
active
07977361
ABSTRACT:
The present invention relates to novel radioactively labeled bioreducible tracers of Formula I useful for detecting hypoxic tumors or ischemic tissue in vivo. In one embodiment, the tracers consist of a 2-nitroimidazole moiety, a triazole, metabolically stable linker with pharmacokinetics enhancing substituents, and a radioisotope. The preferred in vivo imaging modality is positron emission tomography.
REFERENCES:
patent: 5674693 (1997-10-01), Raleigh et al.
patent: 5721265 (1998-02-01), Tracy et al.
patent: 7807394 (2010-10-01), Kolb et al.
patent: 9604249 (1996-02-01), None
patent: 0112575 (2001-02-01), None
Houghten, et al.,Peptides: The Wave of the Future, 2nd International Peptide Symposium in Conjunction with the 17th American Symposium, Jun. 9-14, 2001, San Diego, California.
Adams, G.E. “Hypoxia-mediated Drugs for Radiation and Chemotherapy”, Cancer (1981), 48:696-707.
Bentzen, et al., “Feasibility of Detecting Hypoxia in Experimental Mouse Tumours with 18[F]-fluorinated Tracers and Positron Emission Tomography”, Acta. Oncol. (2000), 39:629-637.
Brizel, et al., “Tumour Oxygenation Predicts for the Likelihood of Distant Metastases in Human Soft Tissue Sarcoma”, Cancer Res., (1996), 56:941-943.
Chao, et al., “A Novel Approach to Overcome Hypoxic Tumor Resistance: Cu-ATSM-Guided Intensity-Modulated Radiation Therapy”, Int. J. Radiat. Oncol. Biol. Phys. (2001), 49:1171-1182.
Fujibayashi, et al., “Copper-62-ATSM: A New Hypoxia Imaging Agent with High Membrane Permeability and Low Redox Potential”, J. Nucl. Med. (1997), 38:1155-1160.
Gronroos, et al., “Pharmacokinetics of [18F]FETNIM: A Potential Hypoxia Marker for PET”, J. Nucl. Med. (2001), 42:1397-1404.
Hockel, et al., “Association between Tumor Hypoxia and Malignant Progression in Advanced Cancer of the Uterine Cervix”, Cancer Res. (1996), 45:4509-4515.
Huisgen, R., “1,3-Dipoloar Clycloadditions—Introduction, Survey, Mechanism”, (Padwa, A., ed.), pp. 1-176, Wiley, 1984.
Evans, et al., “Noninvasive Detection of Tumor Hypoxia Using the 2-Nitroimidazole [18]EF-1”, J. Nucl. Med. (1999), 41(2):327-336.
Ishikawa, et al., “Development of [18F]FRP-170 Injection for Imaging Hypoxia by PET”, Kaku Igaku, (2005), 42:1-10, [Article in Japanese, English Abstract obtained].
Jorgensen, K., “Catalytic Asymmetric Hetero-Diels—Alder Reactions of Carbonyl Compounds and Imines”, Angew. Chem. Int. Ed. Engl. (2000), 39:3558-3588.
Kolb, et al., “Click Chemistry: Diverse Chemical Function from a Few Good Reactions”, Angew. Chem. Int. Ed. (2001), 40:2004-2021.
Kolb, et al., “The Growing Impact of Click Chemistry on Drug Discovery”, Drug Discovery Today (2003), 8:1128-1137.
Krasinski, et al., “Direct Synthesis of 1,5-Disubstituted-4-magnesio-1,2,3-triazoles, Revisited”, Organic Letters (2004), 6:1237-1240.
Lee, et al., “A Potent and Highly Selective Inhibitor of Human alpha-1,3-Fucosyltransferase via Click Chemistry”, J. Chem. Soc. (2003), 125:9588-9589.
Lewis, et al., Click Chemistry in Situ: Acetylcholinesterase as a Reaction Vessel for the Selective Assembly of a Femtomolar Inhibitor from an Array of Building Blocks, Angew. Chem. Int. Ed. (2002), 41:1053-1057.
Manetsch, et al., “In Situ Click Chemistry: Enzyme Inhibitors Made to Their Own Specifications”, J. Am. Chem. Soc. (2004), 126:12809-12818.
Mocharla, et al., “In Situ Click Chemistry: Enzyme-Generated Inhibitors of Carbonic Anhydrase II”, Angew. Chem, Int. Ed. (2005), 44:116-120.
Moulder, et al., “Hypoxic Fractions of Solid Tumors: Experimental Techniques, Methods of Analysis, and a Survey of Existing Data”, Int. J. Radiation Oncology Biol. Phys. (1984), 10:695-712.
Nordsmark, et al., “Pretreatment Oxygenation Predicts Radiation in Response in Advanced Squamous Cell Carcinoma of the Head and Neck”, Radiother. Oncol. (1996), 41:31-39.
Rasey, et al., “Determing Hypoxic Fraction in a Rat Glioma by Uptake of Radiolabeled Fluromisonidazole”, Radiat. Res. (2000), 153:84-92.
Rosotovtsev, et al., “A Stepwise Cycloaddition Process: Copper(I)-Catalyzed Regioselective “Ligation” of Azides and Terminal Alkynes”, Angew. Chem. Int. Ed. (2002), 41:2596-2599.
Seddon, et al., “The Role of Functional and Molecular Imaging in Cancer Drug Discovery and Development”, Brit. J. Radiol. (2003), 76:S128-S138.
Tietze, et al., “Hetero Diels-Alder Reactions in Organic Chemistry”, Top. Curr. Chem. (1997), 189:1-120.
Tornoe, et al., “Peptidotriazoles on Solid Phase: [1,2,3]-Triazoles by Regiospecific Copper(I)-Catalyzed 1,3-Dipolar Cycoladditions of Terminal Alkynes to Azides”, J. Org. Chem. (2002), 67:3057-3064.
Vaupel, et al., “Oxygenation of Human Tumors: Evaluation of Tissue Oxygen Distribution in Breast Cancers by Computerized O2 Tension Measurements”, Cancer Res. (1991), 51:3316-3322.
Wang, et al., “Biconjugation by Copper(I)-Catalyzed Azide-Alkyne [3+2] Cycloaddition”, J. Am. Chem. Soc. (2003), 125:3192-3193.
Wang, et al., “Positron Emission Tomography: Application in Drug Discovery and Drug Development”, Curr. Top. Med. Chem. (2005), 5:1053-1075.
Whiting, et al., “Inhibitors of HIV-1 Protease by Using in Situ Click Chemistry”, Angew. Chem. (2006), 118:1463-1467.
Yang, et al., “Development of F-18-labeled Fluoroerythronitroimidazole as a PET Agent for Imaging Tumor Hypoxia” Radiology (1995), 194:795-800.
Collier Thomas Lee
Duclos Brian A.
Gangadharmath Umesh B.
Gao Zhiyong
Karimi Farhad
Barker Michael
Chu Yong
Ryan Joshua B.
Siemens Medical Solutions USA , Inc.
LandOfFree
Nitro-imidazole hypoxia imaging agent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nitro-imidazole hypoxia imaging agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitro-imidazole hypoxia imaging agent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2711804